In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.

Cigna's Evernorth Health Services said on Wednesday its actions will enhance transparency about the company's negotiations.

Cigna Group plans to limit patients’ out-of-pocket expenses for medications as the insurer faces pressure from Washington ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

According to Bloomberg, a top Cigna executive said it will prevent patients from paying the full list price for drugs, or more than their employer has contributed.

The companies raised prices a median 4%, though some drugs will cost thousands of dollars more.

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

I don’t feel bad for lawmakers very often. But trying to solve the national problem of high health care costs and ...

I don’t feel bad for lawmakers very often. But trying to solve the national problem of high health care costs and accessibility from a state-level perspective is rough. And almost impossible.

Even though some of these "middlemen" are supposed to obtain drugs at a lower price for their clients (ie, insurance companies, pharmacies, hospital systems, et cetera), some argue their fees can ...